Bingham Healthcare’s David Shelley, MD Performs Groundbreaking Minimally Invasive DETOUR arterial Bypass Procedure for Complex Peripheral Arterial Disease
BLACKFOOT, ID ― September 2025 ― Bingham Healthcare is proud to announce that David Shelley MD, a leading vascular specialist, has successfully performed a percutaneous arterial bypass (PTAB) procedure using the innovative DETOUR‚Ñ¢ System. This cutting-edge treatment represents a significant advancement in caring for patients with complex peripheral arterial disease (PAD), offering a minimally invasive alternative to traditional open surgical bypass.
The DETOUR System, manufactured by Endologix LLC, received FDA approval in June 2023 and represents a revolutionary approach to treating long-segment superficial femoral artery (SFA) disease. The procedure enables physicians to bypass arterial blockages by routing stents through the femoral vein to restore blood flow to the leg, avoiding the need for open surgery.
“We are excited to bring this innovative technology to our patients in Eastern Idaho,” said Dr. Shelley. “The DETOUR System provides us with a powerful new tool to help patients with complex peripheral arterial disease who may not be ideal candidates for traditional treatments. This minimally invasive approach can significantly improve patient outcomes while reducing recovery time and complications.”
About the DETOUR System
The DETOUR System is indicated for patients with symptomatic long femoropopliteal occlusions from 200mm to 460mm in length (approximately 8 to 18 inches) with chronic total occlusions or severe blockages. The system is particularly beneficial for patients who:
- Have long, complex arterial blockages
- Have experienced failed previous endovascular procedures
- May not be optimal candidates for open surgical bypass
- Require treatment for critical limb-threatening ischemia
The procedure involves creating a percutaneous bypass using the ENDOCROSS‚Ñ¢ device and TORUS‚Ñ¢ stent grafts, which work together to redirect blood flow around the blocked artery through the adjacent femoral vein.
Clinical Evidence and Outcomes
Clinical trials have demonstrated impressive results for the DETOUR System. Recent data from over 1,000 patients treated worldwide shows strong safety and efficacy outcomes, with clinical success rates exceeding 95% and primary patency rates of approximately 82% at one year. The procedure typically is a same day procedure and rarely requires only a one-day hospital stay compared to several days for open surgery, with patients avoiding the risks associated with general anesthesia and major surgical complications.
“The clinical evidence supporting the DETOUR System is compelling,” noted Dr. Shelley. “Studies show outcomes comparable to open surgical bypass but with significantly reduced invasiveness and faster recovery times. This means our patients can return to their normal activities much sooner.”
Impact on Patient Care
This milestone procedure places Bingham Healthcare among the growing number of leading medical institutions offering PTAB therapy, joining the over 1,000 patients worldwide who have benefited from this innovative treatment since its commercial launch. The addition of the DETOUR System to Bingham Healthcare’s treatment options represents the organization’s ongoing commitment to providing the most advanced care for patients with vascular disease.
Peripheral arterial disease affects millions of Americans and can lead to severe complications including chronic pain, difficulty walking, and in severe cases, limb amputation. Traditional treatment options have included medication, lifestyle changes, balloon angioplasty, stenting, and open surgical bypass. The DETOUR System now provides an important middle ground between less invasive endovascular treatments and major surgery.
Return to Articles
